On ad ban under the Prescription Drug Marketing.docVIP

 PAGE \* MERGEFORMAT 6 On ‘ad ban’ under the Prescription Drug Marketing The provisions of the State Drug Administration from December 1, 2002, all prescription drugs to stop advertising in the mass media. This is what has been said within the lines ‘ad ban’. A ban has always been good at advertising market in China to fight drug production enterprise, a sudden loss of a marketing focus. How to deal with this sudden ban, many pharmaceutical companies chiefs have frowned. Many domestic pharmaceutical production enterprise, both in marketing to emphasize advertising, light (marketing) network problems, appears to know what to do next in the ad ban not surprising. This is the domestic pharmaceutical companies in the long run under non-standard competition problems caused by drug advertisements everywhere, whose products are advertising, who have sold. We do not deny the role of advertising, but the drugs as a special commodity, related to people’s lives, flying advertising not only upset the competitive environment, but also a major cause of high drug prices. The implementation of the ban on advertising is a national operating environment for drugs carried out in a large-scale irregularities, short of its pharmaceutical manufacturing companies will have some effect, but in the long run, this will gradually step of China’s pharmaceutical marketing into the standardized set a good start. How do I break through the ‘ad ban’ on the impact to the pharmaceutical companies, the author based on their experience in the pharmaceutical industry the past few years, summed up the following strategy, willing to work with peers questionable. First, in order to promote the image of driving product sales Domestic pharmaceutical manufacturing enterprises currently exist product promotion and business promotion can not be a good combination of product promotion is a product promotion, corporate promotion of enterprise information, and even companies with little or no publicity